Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PULM | US
-0.01
-0.47%
Healthcare
Biotechnology
30/06/2024
18/10/2024
2.02
2.07
2.07
2.00
Pulmatrix Inc. a clinical stage biotechnology company discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800 a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100 an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix Inc. was founded in 2003 and is headquartered in Lexington Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
42.2%1 month
45.7%3 months
58.8%6 months
52.0%-
-
0.59
0.00
0.00
1.57
0.00
-
-11.14M
7.38M
7.38M
-
-380.22
-
-15.80
-58.99
0.48
0.14
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.20
Range1M
0.22
Range3M
0.97
Rel. volume
1.31
Price X volume
20.33K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Mustang Bio Inc | MBIO | Biotechnology | 0.2174 | 8.09M | 0.14% | n/a | -13.03% |
Alzamend Neuro Inc. Common Stock | ALZN | Biotechnology | 1.675 | 7.50M | 2.13% | n/a | 0.00% |
Moleculin Biotech Inc | MBRX | Biotechnology | 2.585 | 7.35M | 9.53% | n/a | 3.00% |
TFFP | TFFP | Biotechnology | 2.07 | 7.17M | 0.49% | n/a | 1.26% |
Purple Biotech Ltd | PPBT | Biotechnology | 4.37 | 6.84M | 4.55% | n/a | 0.89% |
Aptose Biosciences Inc | APTO | Biotechnology | 0.3643 | 6.60M | 1.19% | n/a | -37.59% |
Adial Pharmaceuticals Inc | ADIL | Biotechnology | 1.01 | 6.47M | 4.11% | n/a | 0.00% |
CDIO | CDIO | Biotechnology | 0.2109 | 6.45M | -0.19% | n/a | 28.31% |
Portage Biotech Inc | PRTG | Biotechnology | 6.13 | 6.43M | -8.64% | 0.27 | 1.47% |
Hoth Therapeutics Inc | HOTH | Biotechnology | 0.9285 | 6.41M | 3.17% | n/a | 0.44% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.538 | 7.80M | -6.65% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2201 | 3.95M | 4.26% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.76M | 1.92% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -12.28% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.38 | 0 | 0.37% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.92 | 0 | -8.84% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4801 | 0 | -10.26% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.045 | 0 | -2.34% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.82 | 0 | 1.93% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 1.57 | 0.53 | Expensive |
Ent. to Revenue | 0.00 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 0.59 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 58.83 | 72.92 | Par |
Debt to Equity | 0.00 | -1.24 | Expensive |
Debt to Assets | 0.00 | 0.25 | Cheaper |
Market Cap | 7.38M | 3.78B | Emerging |